| Similar Articles |
|---|
 |
Bio-IT World
September 2006
Kevin Davies |
Pfizer's Global Survey of Pharmacological Space The pharma blends knowledge, computational chemistry and research informatics to build a unified database. Gathering all the data in one place offered greater control for indexing and data retrieval and management, enabling Pfizer scientists to perform global mapping.   |
Bio-IT World
November 12, 2002
James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success. |
Chemistry World
December 2008 |
Column: In the pipeline I've worked on two drug discovery efforts (one right after the other, as fate would have it) whose final compounds differed by essentially one methyl group from the starting points of each project. |
Chemistry World
October 2010 |
Column: In the pipeline Derek Lowe investigates the comeback combinatorial chemistry has made in the field of drug discovery |
Pharmaceutical Executive
February 1, 2006
Ron Feemster |
Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets. |
Bio-IT World
April 15, 2003
Mark D. Uehling |
Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials. |
Bio-IT World
November 2005
Khaleeli & Fernandez |
Patent Prosecution and Enforcement in Pharmacogenomics Patenting the composition of an isolated nucleic acid sequence, an isolated protein, and small molecules is possible, but there are challenges claiming that they resulted from pharmacogenomic research. |
Bio-IT World
February 10, 2003
Malorye Branca |
Conquering Infinity with Chemical Genetics Harvard superchemist Stuart Schreiber defines the convergence of chemistry and biology. Now the field of chemical genetics is heading toward the clinic. |
Bio-IT World
April 2007
Vicki Glaser |
Software Solutions for Medicinal Chemistry Driven by advances in chemical synthesis, instrumentation, and high-throughput and high-content screening technology, medicinal chemistry's transition from an art to a science is benefiting from a wealth of new software products, spanning both bio- and cheminformatics. |
Bio-IT World
December 10, 2002
Arielle Emmett |
Locus Focus Cheminformatics company Locus Discovery is a technology darling and an entrepreneur's dream, but it faces a dilemma over how much of its proprietary drug discovery software and data to reveal. |
| Knowledge@Wharton |
From Skin Creams to Life Insurance to Medical Care, Biosciences Are the New Frontier of Business Opportunity Research in the biological sciences holds the potential for breakthroughs that could transform the world. But scientific advances also can be baffling and more than a little intimidating, especially for business people... |
Bio-IT World
November 14, 2003
Malorye Branca |
Genomics Provides the Kick Inside New tools and business structures show signs of plumping early-stage pipelines. |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age... |
Chemistry World
June 2008
Sarah Houlton |
Breaking the rules The author finds out about some chemical tricks that can give a new drug the best possible odds of success |
Chemistry World
April 2011 |
Molecular Obesity is Weighing Down Drug Discovery Medicinal chemistry's quest for potent drug candidates has resulted in molecules that are too large and too lipophilic for their own good. |
The Motley Fool
March 31, 2010
Brian Orelli |
When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies. |
Chemistry World
July 26, 2012
Derek Lowe |
Screen shots You might not think that the makeup of a compound screening collection could set off many arguments, but there are a few issues there that will do the trick almost every time. |
Bio-IT World
January 21, 2005 |
Defining 'Integrative Genomics' Five experts from academia and industry discuss the burgeoning field of integrative genomics. |
Chemistry World
May 20, 2015
Katrina Kramer |
Taking the lead on drug discovery Researchers from the UK have developed a straightforward strategy for making compounds that have the potential to become clinical drugs. |
Bio-IT World
November 19, 2004
Lentini & Bent |
Intellectual Property: Patents and Genomic Medicine Patents, so critical to encouraging investment in developing new technologies, threaten to become a legal and economic minefield that could prevent effective commercial exploitation of genomics. |
Bio-IT World
November 12, 2002
Michael Goldman |
A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico? |
Chemistry World
June 2010 |
Column: In the pipeline Derek Lowe looks into his crystal ball to see what the future of medicinal chemistry might be |
Chemistry World
December 2007
Derek Lowe |
Column: In the Pipeline The challenge of biologics. |
Chemistry World
April 2011 |
Column: In the Pipeline If you look over the whole pharmacopeia, you'll see there are a lot of compounds that got their start as natural products. |
Bio-IT World
October 9, 2002
Kevin Davies |
Cracking the 'Druggable Genome' How many potential drug targets are encoded in the human genome? It is a crucial question for every biopharma business. |
Chemistry World
June 2011 |
Column: In the pipeline Chemists are human. Humans are hierarchical. Therefore...well, therefore, you'll find a number of different roles and levels for scientists in a drug company's labs. Here's a rough ordering, from least experienced to most. |
The Motley Fool
February 2, 2010
Brian Orelli |
Shaking Up the Biotech Industry A judge will decide if genes are patentable or not. |
Bio-IT World
June 17, 2004
Hope Melville |
Is It Safe? Think the safe harbor provision in patent law lets you use patented compounds in all preclinical-phase research? Think again. |
Chemistry World
August 2009
Derek Lowe |
Column: In the pipeline The author considers what makes a good looking drug molecule - and how beauty is in the eye of the beholder |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Chemistry World
September 29, 2015 |
Navigating chemical space How big is chemistry? I don't mean how important is it, or how many people do it, but rather, how many molecules are there that we could make? |
Chemistry World
December 1, 2014
Derek Lowe |
Progress at the pace of the slowest Chemistry is a means to an end in drug research, not an end in itself, and that can take some getting used to. It's worth thinking about where chemistry fits into the big picture. |
Chemistry World
May 31, 2009
Nina Notman |
The natural approach to winning at drug discovery High throughput drug screening is often described as a casino, with the odds stacked on the side of success as long as a big enough library is used. |
The Motley Fool
May 25, 2007
Brian Orelli |
Amylin Sifts for Gold The biotech mines extra value from its compound library. Investors, take note. |
Pharmaceutical Executive
June 1, 2005
Peter J. Pitts |
Opinion: Uncle Sam, MD Is having the government pursue a patent the best way of placing important discoveries in the public domain? It depends. Is putting the government in control of drug development in the best interests of public health? No. |
Chemistry World
November 26, 2015
Rebecca Trager |
Drug firms to share chemical compound libraries Anglo-Swedish pharmaceutical firm AstraZeneca and French drug company Sanofi have agreed to exchange 210,000 chemical compounds from their respective proprietary libraries. |
Chemistry World
January 2008
Philip Ball |
Column: The Crucible Does chemical space limit a chemists' creativity? |
Bio-IT World
August 13, 2002
Malorye Branca |
The Proteomics Odyssey Efforts to map the constellation of protein interactions in humans gather momentum as companies vie to provide tools to capitalize on the potential of proteomics. But can proteomics prevail where some feel genomics has failed? |
Chemistry World
July 2, 2013
Derek Lowe |
Target acquired Phenotypic screening has recently seen a revival in popularity. This technique assesses drug candidates first by their effects in some organism, then works back to their causes. It can be an effective strategy, but when you find some interesting results, the need to explain them can become acute. |
| Knowledge@Wharton |
A New Approach to Valuing Biotech Stocks Enormous swings in biotechnology stock prices during the last few weeks show how difficult it is for investors to value biotech companies. It's important to understand the invisible potential locked up in the organizational structure of biotechnology companies... |
Bio-IT World
July 11, 2002
Malorye Branca |
Deep Sequence Diving Like sailors of old, genomic data miners dream of discovering riches and fame. Given the recent improvements in analytics -- and a little more time -- they just might succeed. |
Chemistry World
March 5, 2015
Emma Stoye |
Forgotten synthetic PhD theses set to be given new lease of life A team of researchers have amassed a digital collection of more than 75,000 compounds from PhD theses that might otherwise have mouldered in obscurity. |
Bio-IT World
August 18, 2004
Kevin Davies |
In Praise of Chemical Diversity How to build better small-molecule libraries. |
Chemistry World
September 2007
Derek Lowe |
Column: In the Pipeline Will Phase Zero trials actually help drug development? |
Bio-IT World
November 12, 2002
Andrew W. Torrance |
After the Gene Rush About 20,000 gene-related patents have been granted in the U.S. so far, with twice as many on the way. The practical and political challenges are equally large. |
Chemistry World
October 8, 2008
Sarah Houlton |
Artificial protein chemistry licensed to industry UK researchers are licensing to industry their method of making artificial proteins by chemically modifying individual amino acid structures. |
Chemistry World
August 13, 2015 |
Exploiting the data mine Chemists must embrace open data to allow us to collectively get the best out of the masses of new knowledge we unearth, reports Clare Sansom |
Chemistry World
April 25, 2013
Andreas Barth |
Chemical bibliometrics Counting compounds instead of publications and citations opens new perspectives for data-based scientific discovery and it can complement and stimulate both experimental and theoretical research. |
Pharmaceutical Executive
March 1, 2007 |
Thought Leader: Joseph Brindisi, Kyowa Pharmaceuticals For discovery shops like Kyowa Pharmaceutical, which rely on optimizing the value of compounds in development, managing the pipeline and patent life is a major concern. |
Chemistry World
March 23, 2010 |
Comment: Can we halt the flow of new designer drugs? Could the dangers of 'legal high' mephedrone have been predicted? Of course they could, says John Mann |
